Elevated Serum Soluble ST2 Level is Associated With Increased Plaque Vulnerability in Patients With Non-ST Elevation Acute Coronary Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Distribution of plaque components by QAngioCT
研究概览
简要总结
This study aimed to assess the association between serum sST2 level and plaque vulnerability in ACS patients. It is hypothesized that serum sST2 level may be related to plaque components and closely associated with plaque vulnerability.
详细描述
Serum soluble suppression of tumorigenicity-2 (sST2) has emerged as a novel biomarker of atherosclerotic disease. This study aimed to investigate whether elevated serum sST2 level is related to coronary plaque components detected on coronary computed tomography angiography (CCTA) and plaque vulnerability in non-ST elevation acute coronary syndromes (ACS) patients. 167 lesions in 120 non-ST elevation ACS patients were prospectively enrolled and evaluated by CCTA in this study. Blood were taken from antecubital vein during patient's hospitalization for angiography. Serum sST2 level was measured by commerical ELISA kits (Presage ST2 Assay Kit, Critical Diagnostics). CCTA were performed using a 320-slice CT scanner (Aquilion ONE, Toshiba Medical Systems, Otawara, Japan). Coronary plaque components were analyzed cross each of the lesions using commercialized software package (QAngio CT, Medis, The Netherlands).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of non-ST-elevation ACS
- •Non-ST-elevation myocardial infarction
- •Unstable angina
- •Age from 18 to 75 years
- •Underwent CCTA
排除标准
- •Patients needed an immediate (< 2 h) or early invasive strategy (< 24 h) according to guidelines:
- •Haemodynamic instability
- •Cardiogenic shock
- •Life-threatening arrhythmias or cardiac arrest
- •Mechanical complication
- •Acute heart failure
- •Dynamic ST or T wave changes
- •GRACE score > 140
- •Patients with previous history of:
- •Coronary artery bypass graft surgery or percutaneous coronary intervention (PCI)
- •Immune system disorder
- •Acute/chronic infection
- •Statin use within 3 months
- •Atrial fibrillation
- •End-stage renal failure
- •Iodine-containing contrast allergy
- •Patients with no significant (≥ 50%) stenosis on major epicardial vessels after CCTA performance
- •Patients refused subsequent angiography after CCTA performance
- •Patients with total obstruction on major epicardial vessel
- •Patients with insufficient image quality for QAngioCT analysis
结局指标
主要结局
Distribution of plaque components by QAngioCT
时间窗: Procedure (Coronary CTA )
Hounsfield unit (HU) -30 to 75 for necrotic core, HU 76-130 for fibrous fatty, HU 131-350 for fibrous tissue, and HU over 351 for dense calcium.
次要结局
未报告次要终点